Deuterated testosterone - Lennham Pharmaceuticals
Alternative Names: D-Androgen receptor agonists; D-Androgen receptor agonists - Lennham Pharmaceuticals; d3-testosteroneLatest Information Update: 28 Dec 2025
At a glance
- Originator Lennham Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Androgen receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Breast cancer; Female sexual dysfunction; Hypogonadism
Most Recent Events
- 28 Dec 2025 No recent reports of development identified for preclinical development in Hypogonadism in USA (Parenteral)
- 28 Dec 2025 No recent reports of development identified for preclinical development in Hypogonadism in USA (PO)
- 28 Dec 2025 No recent reports of development identified for preclinical development in Hypogonadism in USA (Transdermal)